(19)

(11)

EP 4 816 391 A1

(12)

(43) Date of publication: 07.10.2026 Bulletin 2026/41 (21) Application number: 24898791.9 (22) Date of filing: 27.11.2024

(51) International Patent Classification (IPC):  C07K 14/715(2006.01) A61P 31/00(2006.01) A61P 37/00(2006.01) C12N 15/85(2006.01) A61K 40/31(2025.01) A61P 35/00(2006.01) C12N 5/0783(2010.01) (52) Cooperative Patent Classification (CPC): C12N 2740/16043; C07K 2319/00; C07K 14/7155; C07K 2319/03; C07K 14/7051; C07K 2319/02; C12N 5/0636; C12N 2510/00; A61K 40/4231; A61K 40/4234; A61K 40/11; A61K 40/31; A61K 40/4205 (86) International application number: PCT/US2024/057810 (87) International publication number: WO 2025/117789 (05.06.2025 Gazette 2025/23)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 01.12.2023 US 202363605426 P 04.12.2023 US 202363605932 P (71) Applicant: Parker Institute For Cancer Immunotherapy San Francisco, California 94129 (US)	(72) Inventor: CONNOLLY, John San Francisco, California 94129 (US) (74) Representative: Brand Murray Fuller LLP  First Floor, 111 Wardour Street London W1F 0UH London W1F 0UH (GB)